Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Building Bridges between Immune-Mediated Inflammatory Diseases in Rheumatology and Gastroenterology
share announcement

Building Bridges between Immune-Mediated Inflammatory Diseases in Rheumatology and Gastroenterology

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 4172

Special Issue Editors

Dr. Catalina Mihai

E-Mail Website
Guest Editor
1. Department of Medical Specialties (I), Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
2. Institute of Gastroenterology and Hepatology, “Sf. Spiridon” Emergency Hospital, Iasi, Romania
Interests: inflammatory bowel disease; hepatitis; ultrasonography; nutrition; non-alcoholic steatohepatitis
Dr. Elena Rezus

E-Mail Website
Guest Editor
1. Department of Rheumatology and Physiotherapy, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
2. I Rheumatology Clinic, Clinical Rehabilitation Hospital, Iasi, Romania
Interests: immune inflammatory rheumatic diseases; cytokines; biological therapy; biomarkers; autoantibodies; genetic predisposition; therapeutic targets; immune response
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We propose this Special Issue, connecting two medical specialties in which there have been huge scientific progress in recent years.

Probably the "tightest" linkage we aim to develop is between autoimmune rheumatic diseases (e.g., rheumatoid arthritis, ankylosing spondylitis, psoriatic arthropathy, etc.) and inflammatory bowel diseases. Both are common and disabling diseases in the young population, with increased costs for the individual and society alike. From common pathological mechanisms and microbiota changes, to common therapies (sulfasalazine, corticosteroids, immunomodulators, biologics and small molecules), there are multiple common links between these conditions. Modern concepts (treat to target, deep remission, clearance of the disease) became the management goals for clinicians in recent years. Understanding both the common things and the differences will lead to deepening our knowledge of the two conditions.

Both the gastrointestinal tract and the liver can be affected by the specific medication for rheumatic diseases, from NSAIDs to cortisone and biological therapies. Liver damage in rheumatic diseases is also a subject of great interest. From risk of viral hepatitis B reactivation under immunosuppressive treatment, to the role of inflammation in the pathogenesis of non-alcoholic steatohepatitis and autoimmune hepatitis, there are multiple unknowns in the liver–joint axis.

We hope that researchers from both specialties, together with those from pathogenesis, morphopathology, dermatology, immunology, pharmacology, etc., will find Special Issue to be the appropriate framework for disseminate their research and knowledge, and to be a springboard for further investigation.

Dr. Catalina Mihai
Dr. Elena Rezus
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immune-mediated inflammatory diseases
  • rheumatoid arthritis
  • ankylosing spondilitis
  • inflammatory bowel disease
  • ulcerative colitis
  • Crohn’s disease
  • biologics
  • anti-TNF
  • autoimmune hepatitis
  • DMARDs

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 403 KiB  
Article
Contrasting Autoimmune Comorbidities in Microscopic Colitis and Inflammatory Bowel Diseases
by Istvan Fedor, Eva Zold and Zsolt Barta
Life 2023, 13(3), 652; https://doi.org/10.3390/life13030652 - 27 Feb 2023
Cited by 2 | Viewed by 2168
Abstract
Background: Inflammatory bowel diseases (Crohn’s disease and ulcerative colitis) and microscopic colitis (lymphocytic and collagenous colitis) are immune-mediated diseases of the gastrointestinal tract, with distinct pathophysiology. Objective: We sought to compare the prevalence of autoimmune diseases between microscopic colitis (MC) and inflammatory bowel [...] Read more.
Background: Inflammatory bowel diseases (Crohn’s disease and ulcerative colitis) and microscopic colitis (lymphocytic and collagenous colitis) are immune-mediated diseases of the gastrointestinal tract, with distinct pathophysiology. Objective: We sought to compare the prevalence of autoimmune diseases between microscopic colitis (MC) and inflammatory bowel diseases (IBDs) in our patient cohorts in their medical history. Methods: We collected data from 611 patients (508 with IBD, 103 with MC). We recorded cases of other autoimmune diseases. The screened documentation was written in the period between 2008 and 2022. We sought to determine whether colonic involvement had an impact on the prevalence of autoimmune diseases. Results: Ulcerative colitis patients and patients with colonic-predominant Crohn’s disease had a greater propensity for autoimmune conditions across the disease course than patients with ileal-predominant Crohn’s disease. Gluten-related disorders were more common in Crohn’s disease than in ulcerative colitis, and slightly more common than in microscopic colitis. In ulcerative colitis, 10 patients had non-differentiated collagenosis registered, which can later develop into a definite autoimmune disease. Conclusions: Predominantly colonic involvement can be a predisposing factor for developing additional autoimmune disorders in IBD. Ulcerative colitis patients may have laboratory markers of autoimmunity, without fulfilling the diagnostic criteria for definitive autoimmune disorders (non-differentiated collagenosis). Full article
(This article belongs to the Special Issue Building Bridges between Immune-Mediated Inflammatory Diseases in Rheumatology and Gastroenterology)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 730 KiB  
Review
Inflammatory Bowel Disease as a Paradoxical Reaction to Anti-TNF-α Treatment—A Review
by Ioana Ruxandra Mihai, Alexandra Maria Burlui, Ioana Irina Rezus, Cătălina Mihai, Luana Andreea Macovei, Anca Cardoneanu, Otilia Gavrilescu, Mihaela Dranga and Elena Rezus
Life 2023, 13(8), 1779; https://doi.org/10.3390/life13081779 - 20 Aug 2023
Cited by 2 | Viewed by 1700
Abstract
TNF-α inhibitors (TNFis) have revolutionized the treatment of certain chronic immune-mediated diseases, being widely and successfully used in rheumatic inflammatory diseases, and have also proved their efficacy in the treatment of inflammatory bowel disease (IBD). However, among the side effects of these agents [...] Read more.
TNF-α inhibitors (TNFis) have revolutionized the treatment of certain chronic immune-mediated diseases, being widely and successfully used in rheumatic inflammatory diseases, and have also proved their efficacy in the treatment of inflammatory bowel disease (IBD). However, among the side effects of these agents are the so-called paradoxical effects. They can be defined as the appearance or exacerbation of a pathological condition that usually responds to this class of drug while treating a patient for another condition. A wide range of paradoxical effects have been reported including dermatological, intestinal and ophthalmic conditions. The causal mechanism of occurrence may implicate an imbalance of cytokines, but is still not fully understood, and remains a matter of debate. These paradoxical reactions often show improvement on discontinuation of the medication or on switching to another TNFi, but in some cases it is a class effect that could lead to the withdrawal of all anti-TNF agents. Close monitoring of patients treated with TNFis is necessary in order to detect paradoxical reactions. In this study we focus on reviewing IBD occurrence as a paradoxical effect of TNFi therapy in patients with rheumatological diseases (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis). Full article
(This article belongs to the Special Issue Building Bridges between Immune-Mediated Inflammatory Diseases in Rheumatology and Gastroenterology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop